Skip to main content

Retinoschisis

3
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
IVB102 InjectionPhase 1
InnoVec Biotherapeutics
1 program
1
IVB102 InjectionPhase 1
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
IVB102 InjectionPhase 11 trial
Active Trials
NCT06289452Active Not Recruiting18Est. Dec 2029

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
2029
UNION therapeuticsIVB102 Injection

Clinical Trials (1)

Total enrollment: 18 patients across 1 trials

Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis

Start: Mar 2024Est. completion: Dec 202918 patients
Phase 1Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.